What are the key differences in efficacy and mechanism between Semaglutide, Tirzepatide, and Retatrutide for weight loss?

Semaglutide, a GLP-1 agonist, typically yields 15-20% weight loss over 68 weeks in studies with 1,961 participants. Tirzepatide, a dual GLP-1/GIP agonist, achieves superior results of 20-25% over 72 weeks by activating two incretin pathways. Retatrutide, the emerging triple GLP-1/GIP/Glucagon agonist, shows the highest efficacy in Phase 2 trials, with 24-26% weight loss in 48 weeks by targeting three distinct metabolic pathways.

How does AOD-9604 facilitate weight loss and what makes it a distinct option compared to GLP-1 peptides?

AOD-9604, a growth hormone fragment, promotes fat loss by enhancing lipolysis without impacting blood sugar or insulin levels. Clinical data indicates an average 4-6% weight loss over 12 weeks in studies with 300 participants. This mechanism distinguishes it from GLP-1s, making it suitable for targeted fat reduction and body recomposition, often with minimal reported side effects like injection site soreness.

What post-Ozempic protocols or peptide strategies are effective for maintaining weight loss and preventing rebound after discontinuing GLP-1 agonists?

To counter the 'rebound problem' after GLP-1 cessation, a strategic 'GLP-1 Transition Stack' is crucial for metabolic reset and muscle preservation. Peptides like AOD-9604 can continue to target fat oxidation, while growth hormone-releasing peptides such as CJC-1295/Ipamorelin help preserve lean muscle mass, which is vital for sustained metabolic health and preventing weight regain.

Why is peptide stacking recommended for optimizing body composition, and what are some examples?

Peptide stacking provides a synergistic approach, targeting multiple metabolic pathways for enhanced body composition outcomes. For example, a 'Body Recomposition Stack' might combine AOD-9604 for targeted fat loss with CJC-1295/Ipamorelin to stimulate growth hormone release for lean muscle preservation and growth, often supported by BPC-157 for recovery. This multi-faceted strategy can yield superior results compared to single-peptide use, especially when combined with resistance training.

How does 5-Amino-1MQ specifically contribute to metabolic weight loss by targeting fat cells?

5-Amino-1MQ promotes metabolic weight loss by inhibiting nicotinamide N-methyltransferase (NNMT), an enzyme primarily found in fat cells that drives fat storage. By blocking NNMT, 5-Amino-1MQ redirects metabolic processes within adipocytes towards energy expenditure rather than accumulation, thereby reducing adipose tissue and improving overall metabolic flexibility. This makes it a targeted approach within the adipokine regulation pathway.

PeptideKey Guides

Metabolic Weight Loss Peptides Guide: Move the Scale [2026]

Uncover top metabolic and weight management peptides. Our 2026 guide provides research insights, safety data, and comparison criteria for informed decisions.

This page is part of PeptideKey's evidence-based peptide research library covering 100+ compounds with lab-verified purity data.